Skip Navigation


NDT Advance Access originally published online on September 8, 2008
Nephrology Dialysis Transplantation 2008 23(12):3762-3766; doi:10.1093/ndt/gfn503
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
23/12/3762    most recent
gfn503v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by de Miguel, D.
Right arrow Articles by Burgaleta, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Miguel, D.
Right arrow Articles by Burgaleta, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs

Dunia de Miguel, Julio García-Suárez, Yolanda Martín, Juan José Gil-Fernández and Carmen Burgaleta

Service of Haematology, Department of Medicine, Príncipe de Asturias University Hospital, University of Alcalá, Alcalá de Henares, Madrid, Spain

Correspondence and offprint requests to: Dunia de Miguel, Servicio de Hematología, Hospital Universitario Príncipe de Asturias, Carretera Alcalá-Meco S/N (Campus Universitario), 28805 Alcalá de Henares, Madrid, Spain. Tel: +34-91-8878100; Fax: +34-91-8812510; E-mail: duniamll@hotmail.com

Keywords: gemfibrozil; high-dose methotrexate; piperacillin—tazobactam; risk factors; severe renal failure

The first 150 words of the full text of this article appear below.



   Introduction
 
High-dose methotrexate (HDMTX, >1 g/m2) administered as an intravenous (i.v.) infusion is an important component in the treatment regimens for a variety of cancers [1]. HDMTX-associated severe acute renal failure (ARF) is an infrequent but serious complication because MTX is predominantly excreted in the urine. Data from a number of studies performed in the 1970s showed that a sustained elevation of serum MTX concentrations at 24 h (≥5 µmol/L), 48 h (≥1 µmo/L) and 72 h (≥0.1 µmo/L) after the start of the MTX infusion is considered to be toxic. The usual serum MTX level 48 h after HDMTX is <0.1 µmol/L. In the era of optimal supported care the incidence of grade 3–4 ARF after HDMTX has decreased from 10% to 0.6% in solid-cancer patients [2]. However, to our knowledge, the current incidence of HDMTX-associated severe ARF is unknown in adult . . . [Full Text of this Article]



   Methods
 
Patients
Study design and patient monitoring
Analysis of risk factors
Treatment strategies


   Results
 
Incidence and clinical findings
Patient 1
Patient 2
Risk factors


   Discussion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?